Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReConnect
- Development stage
- Unknown
- Lead developer
- Young Living
- Administration
- Topical, Inhalation
01
Overview
ReConnect is a proprietary essential oil blend developed by Young Living, specifically formulated to support mental focus, emotional grounding, and a positive outlook. The formulation is a complex mixture of several essential oils, including Sacred Frankincense (*Boswellia sacra*), Melissa (*Melissa officinalis*), Lavender (*Lavandula angustifolia*), Myrrh (*Commiphora myrrha*), Sandalwood (*Santalum album*), and others. It has been evaluated in clinical research, specifically a Phase 2 trial (NCT02382263), for its potential to improve quality of life, relaxation, and sleep patterns in children aged 3 to 9 with Autism Spectrum Disorder (ASD). The blend is intended for aromatic or topical use.
- Brand names
- ReConnect
- Other names
- Young Living ReConnectReconnect Essential Oil
Beyond the preview
Go deeper on ReConnect.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReConnect.